The abstract is read at the publisher; the summary is JClub's.
Combined CHIR99021 and IFN-γ licensing of human bone marrow-derived MSCs yields COMBO conditioned media that transiently pauses hyperglycaemia and prolongs survival in NOD mice, reaching 32±2 days.
- Why it matters: Ongoing autoimmunity in type 1 diabetes may limit whether MSC secretomes can still regenerate islets and suppress immune attack, so persistence of benefit during disease progression is unclear.
- What they did: MSCs were licensed for 24 h with CHIR99021, IFN-γ, or both, then concentrated conditioned media were injected intrapancreatically into female NOD mice; glycaemia, insulitis, immune composition, and label-free secretome proteomics were assessed.
- The result: COMBO conditioned media given after hyperglycaemia onset reduced severe insulitis and delayed diabetes in prevention studies by 4 weeks (21±0.9 vs 17±0.4), with COMBO proteomics showing upregulation of tolerogenic effectors like CD274/PD-L1 and IDO1.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.